Piero Pileri

Piero Pileri

Auto-generated profile, based on publicly available information

Piero Pileri

Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2021 in Nature
Verified
Journal Article
Open access
PDF file
EAEmanuele Andreano
Emanuele Andreano
IPIda Paciello
Ida Paciello
GPGiulia Piccini
Giulia Piccini
NMNoemi Manganaro
Noemi Manganaro
PPPiero Pileri
Piero Pileri
RRRino Rappuoli
Rino Rappuoli
The emergence of SARS-CoV-2 variants is jeopardizing the effectiveness of current vaccines and limiting the application of monoclonal antibody-based therapy for COVID-19 (refs. 1,2). Here we analysed the memory B cells of five naive and five convalescent people vaccinated with the BNT162b2 mRNA vaccine to investigate the nature of the B cell and antibody response at the single-cell level. Almost 6,000 cells were sorted, over 3,000 cells produced monoclonal antibodies against the spike protein and more than 400 cells neutralized the original SARS-CoV-2 virus first identified in Wuhan, China. The B.1.351 (Beta) and B.1.1.248 (Gamma) variants escaped almost 70% of these antibodies, while a much smaller portion was impacted by the B.1.1.7 (Alpha) and B.1.617.2 (Delta) variants. The overall loss of neutralization was always significantly higher in the antibodies from naive people. In part, this was due to the IGHV2-5;IGHJ4-1 germline, which was found only in people who were convalescent and generated potent and broadly neutralizing antibodies. Our data suggest that people who are seropositive following infection or primary vaccination will produce antibodies with increased potency and breadth and will be able to better control emerging SARS-CoV-2 variants.

1 June 2018 in Journal of Controlled Release
Verified
Journal Article
Closed access
RGRenata Grifantini
Renata Grifantini
Monia TarantaMonia Taranta
Monia Taranta
LGLisa Gherardini
Lisa Gherardini
INIlaria Naldi
Ilaria Naldi
MPMatteo Parri
Matteo Parri
Caterina CintiCaterina Cinti
Caterina Cinti

12 May 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
JTJonathan L. Torres
Jonathan L. Torres
GOGabriel Ozorowski
Gabriel Ozorowski
EAEmanuele Andreano
Emanuele Andreano
HLHejun Liu
Hejun Liu
JCJeffrey Copps
Jeffrey Copps
AWAndrew Ward
Andrew Ward
Significance: Clinical candidate monoclonal antibody J08 binds the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) S-protein independent of known escape mutations and is able to potently neutralize most variants of concern (VoCs). Here, we explore these properties using cell-based assays and structural studies. A relatively small epitope footprint high on the receptor binding domain (RBD) ridge and the ability to bind multiple conformational states of the S-protein contribute to strong neutralization across several variants.

4 January 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
EAEmanuele Andreano
Emanuele Andreano
IPIda Paciello
Ida Paciello
GPGiulio Pierleoni
Giulio Pierleoni
GPGiulia Piccini
Giulia Piccini
VAValentina Abbiento
Valentina Abbiento
RRRino Rappuoli
Rino Rappuoli
The continuous evolution of SARS-CoV-2 generated highly mutated variants able to escape natural and vaccine-induced primary immunity. The administration of a third mRNA vaccine dose induces a secondary response with increased protection. Here we investigate the longitudinal evolution of the neutralizing antibody response in four donors after three mRNA doses at single-cell level. We sorted 4100 spike protein specific memory B cells identifying 350 neutralizing antibodies. The third dose increases the antibody neutralization potency and breadth against all SARS-CoV-2 variants as observed with hybrid immunity. However, the B cell repertoire generating this response is different. The increases of neutralizing antibody responses is largely due to the expansion of B cell germlines poorly represented after two doses, and the reduction of germlines predominant after primary immunization. Our data show that different immunization regimens induce specific molecular signatures which should be considered while designing new vaccines and immunization strategies.

7 October 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
EAEmanuele Andreano
Emanuele Andreano
ENEmanuele Nicastri
Emanuele Nicastri
IPIda Paciello
Ida Paciello
PPPiero Pileri
Piero Pileri
NMNoemi Manganaro
Noemi Manganaro
RRRino Rappuoli
Rino Rappuoli
Human monoclonal antibodies are safe, preventive and therapeutic tools, that can be rapidly developed to help restore the massive health and economic disruption caused by the Covid-19 pandemic. By single cell sorting 4277 SARS-CoV-2 spike protein specific memory B cells from 14 Covid-19 survivors, 453 neutralizing antibodies were identified and 220 of them were expressed as IgG. Up to 65,9% of monoclonals neutralized the wild type virus at a concentration of >500 ng/mL, 23,6% neutralized the virus in the range of 100 - 500 ng/mL and 9,1% had a neutralization potency in the range of 10 - 100 ng/mL. Only 1,4% neutralized the authentic virus with a potency of 1-10 ng/mL. We found that the most potent neutralizing antibodies are extremely rare and recognize the RBD, followed in potency by antibodies that recognize the S1 domain, the S-protein trimeric structure and the S2 subunit. The three most potent monoclonal antibodies identified were able to neutralize the wild type and D614G mutant viruses with less than 10 ng/mL and are good candidates for the development of prophylactic and therapeutic tools against SARS-CoV-2. One Sentence Summary Extremely potent neutralizing human monoclonal antibodies isolated from Covid-19 convalescent patients for prophylactic and therapeutic interventions.

26 January 2021 in Cell Death & Differentiation
Verified
Journal Article
Closed access
PDF file
SPSimone Pecetta
Simone Pecetta
MPMariagrazia Pizza
Mariagrazia Pizza
CSClaudia Sala
Claudia Sala
EAEmanuele Andreano
Emanuele Andreano
PPPiero Pileri
Piero Pileri
RRRino Rappuoli
Rino Rappuoli